Latest Safety News

Norwest Minerals Limited has launched a $4.85 million entitlement offer to fund an aggressive drilling campaign and mining option review at its Bulgera Gold project, aiming to significantly expand its gold resource amid soaring gold prices.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Pointerra Limited’s Q3 FY25 results reveal delayed invoicing milestones pushed into Q4, yet strong progress across multiple sectors and promising product development underpin an optimistic cashflow outlook.

Constellation Technologies Limited reports sustained sales growth and positive cash flow in Q3 2025, driven by its Callisto Food Safety & Compliance system and strategic market expansion.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Beonic Limited reported a 6.5% increase in annual recurring revenue to $17.8 million and a significant gross margin improvement to 75.5%, driven by new global contracts and disciplined cost management. The company targets cash flow breakeven in Q4 FY25 and an EBITDA margin of up to 15%.

INOVIQ Limited reports significant progress in its exosome-based cancer diagnostics and therapeutics, including expanded customer adoption, advanced AI screening tests, and strategic partnerships with leading research centres.

Westgold Resources reported a record A$80 million increase in cash, bullion, and liquid investments in Q3 FY25, maintaining steady gold production and cost guidance while advancing key mine ramp-ups and strategic divestments.

Jupiter Mines reported a robust Q3 FY2025 with higher manganese production and sales at Tshipi, driving a 65% jump in EBITDA amid improved prices and reduced costs.

Northern Minerals has made significant progress on its Browns Range Heavy Rare Earths Project, advancing its feasibility study and exploration while raising $41.5 million, positioning itself as a strategic alternative amid growing geopolitical supply risks.

Percheron Therapeutics has discontinued its ATL1103 program and curtailed investment in ATL1102 following underwhelming trial results, while advancing talks to in-license new rare disease therapies and extending its cash runway into FY2027.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.